Opinion|Videos|March 20, 2025

Additional Data Needs for BTK Inhibitors in CSU

Panelists discuss how future research should focus on identifying biomarkers for patient selection, understanding long-term safety profiles, exploring combination therapy approaches, and determining optimal treatment duration with Bruton tyrosine kinase (BTK) inhibitors in chronic spontaneous urticaria (CSU).

Video content above is prompted by the following:

  • What additional data, if any, is needed surrounding BTK inhibitors and CSU?

Latest CME